{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:21Z","timestamp":1792718361327,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002418","name":"Intel Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.10.016","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T01:56:53Z","timestamp":1571018213000},"page":"412-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study"],"prefix":"10.1016","volume":"82","author":[{"given":"Elise A.","family":"Olsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Kornacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Hordinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.10.016_bib1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/archderm.1992.01680150136027","article-title":"Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey","volume":"128","author":"Safavi","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaad.2017.10.048","article-title":"Objective outcome measures: collecting meaningful data on alopecia areata","volume":"79","author":"Olsen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2007.10.645","article-title":"Subcutaneous efalizumab is not effective in the treatment of alopecia areata","volume":"58","author":"Price","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/jid.1950.52","article-title":"Alopecia areata: a statistical study and consideration of endocrine influences","volume":"14","author":"Walker","year":"1950","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaad.2012.06.006","article-title":"Multivariate analysis of prognostic factors in patients with rapidly progressive alopecia areata","volume":"67","author":"Uchiyama","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib7","first-page":"421","article-title":"A new classification of alopecia areata","volume":"131","author":"Ikeda","year":"1965","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2019.10.016_bib8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1136\/bmj.2.4691.1250","article-title":"Alopecia areata: a clinical study","volume":"2","author":"Anderson","year":"1950","journal-title":"Br Med J"},{"key":"10.1016\/j.jaad.2019.10.016_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0190-9622(91)70032-W","article-title":"Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone","volume":"24","author":"van der Steen","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib10","first-page":"129","article-title":"Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance","volume":"192","author":"Weise","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.10.016_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.det.2012.08.014","article-title":"Genetic basis of alopecia areata: a roadmap for translational research","volume":"31","author":"Jabbari","year":"2013","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2019.10.016_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2019.10.016_bib13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2019.10.016_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata: an appraisal of new treatment approaches and overview of current therapies","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2019.10.016_bib16","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2019.10.016_bib17","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2019.10.016_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib19","series-title":"JAKAFI\u00ae (ruxolitinib) [package insert]","year":"2019"},{"key":"10.1016\/j.jaad.2019.10.016_bib20","series-title":"XELJANZ\u00ae (tofacitinib) [package insert]","year":"2018"},{"key":"10.1016\/j.jaad.2019.10.016_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines\u2014Part II: National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib22","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/jidsymp.2013.4","article-title":"Overview of alopecia areata","volume":"16","author":"Hordinsky","year":"2013","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2019.10.016_bib23","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.110.033787","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans","volume":"38","author":"Shilling","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jaad.2019.10.016_bib24","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2019.10.016_bib25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2133.1997.tb03777.x","article-title":"Topical FK506: a\u00a0potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model","volume":"137","author":"McElwee","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.10.016_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaad.2004.05.019","article-title":"Topical tacrolimus in alopecia areata","volume":"52","author":"Price","year":"2005","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219328981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219328981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:03:47Z","timestamp":1778508227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219328981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0190962219328981"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.10.016","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}